zum Inhalt springen
Powered by

TRANSVAC: New Vaccines Faster

Förderung durch:
EU-Mitgliedsstaaten oder EU-assoziierte Staaten, sowie mit Horizon 2020 assoziierte Staaten

Folgende Informationen sind nur auf Englisch verfügbar:

Next Call Launch at 15 June 2021!

Vaccines are one of the most successful and cost-effective public health tools for disease prevention. However, their development is time-consuming and complex, requiring a combination of specialised skills and technical capacities not readily available at a single organisation. In order to facilitate access to these skills and capacities, and to promote collaborations in the European vaccine landscape - aiming thereby to accelerate the development of safe, effective and affordable vaccines - the EC, in the context of the Horizon 2020 Framework Programme, has recently funded “TRANSVAC2”, a European vaccine research and development (R&D) infrastructure.

TRANSVAC2 builds upon the success of TRANSVAC, the European Network of Vaccine Research and Development funded under the EC´s previous Framework Programme (FP7). TRANSVAC made significant contributions to the European vaccine development landscape, providing scientific-technical services to more than 29 vaccine projects and developing a roadmap for the establishment of a sustainable European vaccine R&D.

This project has received funding from the European Union's Horizon 2020 research and innovation programme.

Applicants must use the Application form and submit it in PDF format by e-mail to transvacinfo(at)euvaccine.eu. Any paper versions of applications will be rejected.

Applications not containing essential information (e.g. on methodology) cannot be properly evaluated for feasibility. For scientific questions regarding a specific Service, please contact the corresponding lead scientist directly (listed in the service description). For questions regarding any aspect of the submission, review or associated administration please contact the TRANSVAC Management Team.

Who should apply

The rules governing use of the Services offered by TRANSVAC are those laid down by the European Commission (EC). Please note that the TRANSVAC partners are unable to make exceptions to any of these rules. The term “Users” refers to an external group (or external individual) who is selected to access the Services offered by TRANSVAC.

Through a peer-reviewed competitive process, European groups may apply to benefit from the expertise, reagents, and facilities of the TRANSVAC project. The Services are not restricted to any disease in particular. For scientists based in countries outside the EU Member States or its Associated States, access is subject to a range of charges according to the Service in question.

According to the EC regulations applicants must comply with the following criteria:

  1. The User group leader and the majority of the Users in the group must work in an institution established in a EU Member State or Associated State (Associated States: Iceland, Norway, Albania, Bosnia and Herzegovina, the former Yugoslav Republic of Macedonia, Montenegro, Serbia, Turkey, Israel, Moldova, Switzerland, Faroe Islands, Ukraine, Tunisia, Georgia, Armenia);

  2. Additionally 20% of Users of a specific service can be of non-EU countries Associated to Horizon 2020 as listed in the document H2020 Programme Funding of applicants from non-EU countries & international organisations.

  3. The User group leader and the majority of the Users in the group must work in a different country than the TRANSVAC partner whose Service they wish to access

  4. Only Users that are able to openly disseminate the results they have generated with the support of TRANSVAC may apply.

Seiten-Adresse: https://www.gesundheitsindustrie-bw.de/datenbank/foerderungen/transvac-new-vaccines-faster